Generate Biomedicines, Inc.
GENBNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 1Active Not Recruitingreadout ~2026-08-30Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GB-7624 in Healthy Adult Participants
- Phase 1Active Not Recruitingreadout ~2027-05A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
- Phase 1Recruitingreadout ~2027-06Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
- Phase 3Recruitingreadout ~2028-12A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
- Phase 3Recruitingreadout ~2029-01A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Flagship Pioneering, LlcPassive (13G)May 15, 2026
- Nally MichaelPassive (13G)May 15, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Nally MichaelOfficer — Chief Executive Officer | Mar 4, 2026 | Buy | 20,000 | $12.00 |
| Grous BethOfficer — Chief People Officer | Mar 2, 2026 | Buy | 300 | $16.00 |
| Silvers JasonOfficer — President & CFO | Mar 2, 2026 | Buy | 500 | $16.00 |
| Afeyan NoubarDirector | Mar 2, 2026 | Conversion | 12.7M | — |
| Nally MichaelOfficer — Chief Executive Officer | Mar 2, 2026 | Conversion | 658,327 | — |
| Bancel StephaneDirector | Mar 2, 2026 | Conversion | 724,160 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.5M | 8.5 | +8.7% |
| Apr 30, 2026 | 3.2M | 9.7 | +53.0% |
| Apr 15, 2026 | 2.1M | 5.9 | +52.5% |
| Mar 31, 2026 | 1.4M | 3.9 | +52.5% |
| Mar 13, 2026 | 893,427 | 1.0 | +100.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recentEvents the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.